The Reason Prescription Drugs Will Never Be Developed Fast!

TL;DR

Sotorasib, a new lung cancer drug, went through decades of research and development, starting from basic research to applied research and experimental development. It targets cancers caused by the KRAS gene mutation and has shown promising results in clinical trials.

Transcript

Thank you to Magic Spoon for sponsoring today’s episode! Go to magicspoon.com/SciShow and use the code SciShow at checkout to get $5 off any order. [♪ INTRO] Creating a new medication takes years, and sometimes decades, of work. Sotorasib, a recently approved lung cancer drug, might seem super new, but it has a story starting with research in the 8... Read More

Key Insights

• 👨‍🔬 Drug research and development involves multiple stages, including basic research, applied research, and experimental development.
• 🎯 Understanding the target gene and its mutation is crucial for developing effective drugs.
• 🎯 Creating drugs for previously considered "undruggable" targets requires innovative approaches and extensive experimentation.
• 😒 Clinical trials are essential in determining the safety and efficacy of drug candidates before they can be approved for use in patients.
• 🤞 The approval of sotorasib provides hope for patients with non-small cell lung cancer with a KRAS mutation who have not responded to standard treatments.
• 👶 Continued research and development are necessary to improve existing drugs and develop new treatment options for cancer patients.

Questions & Answers

Q: How does the KRAS gene mutation lead to cancer?

When the KRAS gene undergoes a mutation, the resulting protein becomes constantly active, driving uncontrolled cell growth, which is a hallmark of cancer.

Q: What were the challenges faced in developing a drug for the KRAS gene mutation?

The mutant K-Ras protein was initially considered "undruggable" due to its smooth surface, making it difficult to find a target for drugs. Additionally, any drug developed had to be specific to the mutant protein and spare healthy proteins.

Q: How did researchers overcome the challenges in developing a drug for the KRAS gene mutation?

Researchers discovered a small groove on the mutant K-Ras protein's surface that was only visible when the protein was in its inactive state. They designed molecules that could bind to this groove and inhibit the protein's activity, leading to the development of sotorasib.

Q: What were the results of clinical trials for sotorasib?

Clinical trials showed that sotorasib (ARS-510) and other drug candidates by Amgen and Mirati Therapeutics could shrink tumors in patients with non-small cell lung cancer with a KRAS mutation. Some patients saw significant tumor regression, leading to the approval of sotorasib by the FDA.

Summary & Key Takeaways

• Sotorasib, a lung cancer drug, was approved by the FDA in May 2021 for treating lung cancers caused by the KRAS gene mutation.

• The journey of creating sotorasib involved three stages of research and development: basic research, applied research, and experimental development.

• Researchers discovered a small groove on the surface of the mutant K-Ras protein, leading to the development of molecules that target and inhibit its activity, ultimately leading to the creation of sotorasib.